Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 15/20 | 0.42 |
| ▸ | HTR2A | P28223 | 14/20 | 0.37 |
| ▸ | HTR2B | P41595 | 14/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | CYP8B1 | Q9UNU6 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947948 | 0.92 | HTR2C (0.41) | HTR2CHTR2AHTR2BCNR2HPGD | |
| SCHEMBL10219096 | 0.84 | HTR2C (0.57) | HTR2CHTR2AHTR2BHPGDSPR | |
| SCHEMBL2571551 | 0.83 | HTR2C (0.47) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL9948180 | 0.83 | HTR2C (0.56) | HTR2CHTR2AHTR2BHPGD | |
| SCHEMBL9947850 | 0.82 | HTR2C (0.49) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL9948430 | 0.81 | HTR2C (0.41) | HTR2CHTR2AHTR2B | |
| SCHEMBL10217200 | 0.81 | HTR2C (0.45) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL10219107 | 0.80 | HTR2C (0.55) | HTR2CHTR2AHTR2B | |
| SCHEMBL9947883 | 0.79 | HTR2C (0.47) | HTR2CHTR2AHTR2BMAPT | |
| SCHEMBL10217503 | 0.79 | HTR2C (0.47) | HTR2CHTR2AHTR2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346816-B2 | 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-06 | — | — | US | disclosed |
| EP-2384328-B1 | 6,7,8,9-TETRAHYDRO-5H-1,4,7,10A-TETRAAZA-CYCLOHEPT[F]INDENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR PREPARING THEM | BOEHRINGER INGELHEIM INT (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165304-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | HTR2C 2/4885HTR2A 9/4885HTR2B 14/4885 |
| US-20140066428-A1 | 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | HTR1A, HTR2C, TPH1 | HTR2C 2/4885HTR2A 7/4885HTR2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.